Coffin-Lowry Syndrome
Also known as: CLS, Mental Retardation with Facial and Digital Anomalies, Fifth Digit Syndrome
Coffin-Lowry syndrome (CLS) is a rare genetic disorder characterized by intellectual disability, distinctive facial features, skeletal abnormalities, and growth retardation. It primarily affects males, with females typically exhibiting milder symptoms. The syndrome is caused by mutations in the RPS6KA3 gene, which plays a crucial role in cell signaling and brain development.
Coffin-Lowry Syndrome is a rare problem that makes it hard for your brain to learn and your body to grow normally. It changes how your face looks and can make your bones a little different. Doctors and therapists can help you learn and be as healthy as possible.
Signs & Symptoms
- Intellectual disability (moderate to severe)
- Distinctive facial features (e.g., prominent forehead, hypertelorism, thick lips)
- Skeletal abnormalities (e.g., kyphoscoliosis, pectus excavatum)
- Growth retardation
- Tapered fingers with short, broad thumbs
- Hypotonia (muscle weakness)
- Hearing loss
- Cardiac anomalies (less common)
- Behavioral problems (e.g., hyperactivity, aggression)
Treatment Options
Educational and behavioral therapies
SUPPORTIVEPhysical therapy
SUPPORTIVESpeech therapy
SUPPORTIVEOccupational therapy
SUPPORTIVEMedications for behavioral problems (e.g., ADHD)
MODERATELY EFFECTIVESurgical correction of skeletal abnormalities (e.g., scoliosis)
MODERATELY EFFECTIVEManagement of cardiac anomalies
SUPPORTIVEDiagnosis
- Clinical evaluation
- Physical examination
- Radiological studies (X-rays)
- Genetic testing (RPS6KA3 gene sequencing)
- Molecular Genetic Testing
History
Coffin-Lowry syndrome was first described independently by Dr. Grange S. Coffin in 1966 and Dr. Robert Lowry in 1971. The genetic basis of the syndrome was identified in 1996 with the discovery of mutations in the RPS6KA3 gene.
Recent Breakthroughs
Novel therapeutic targets for Coffin-Lowry Syndrome identified through iPSC-derived neuronal models
Research using induced pluripotent stem cells (iPSCs) derived from individuals with CLS has identified potential therapeutic targets for improving neuronal function and cognitive outcomes. Specifically, modulation of specific signaling pathways downstream of RSK2 showed promise in preclinical studies.
Longitudinal study reveals progression of skeletal abnormalities in Coffin-Lowry Syndrome
A longitudinal study tracking skeletal changes in individuals with CLS over several years has provided valuable insights into the progression of kyphoscoliosis and other skeletal abnormalities. This information can help guide orthopedic management and improve patient outcomes.